Takeda pays Keros $200M upfront for rival to BMS' booming blockbuster Reblozyl

Takeda is paying Keros Therapeutics $200 million upfront to bolster its late-stage cancer pipeline. The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with Bristol Myers Squibb’s Reblozyl in blood cancer indications.